Acquisition of Ceregene (Tables)

12 Months Ended

Dec. 31, 2014

Summary of Estimated Fair Value of Consideration Transferred

The following table summarizes the estimated fair value of the consideration transferred by Sangamo to the Ceregene stockholders on the Closing Date (in thousands):

Sangamo shares of common stock	$	1,200
Contingent earn-out		1,510
Total purchase consideration	$	2,710

Summary of Estimated Fair Value of Net Assets Acquired

The following table summarizes the estimated fair value of the net assets acquired as of the Closing Date (in thousands):

Cash and equivalents	$	79
Accounts receivable		22
Identifiable intangible assets		1,870
Goodwill		1,585
Total assets acquired		3,556
Deferred tax liability		(748	)
Accounts payable and accrued liabilities		(98	)
Total liabilities assumed		(846	)
Net assets acquired	$	2,710

Summary of Assets, Estimated Fair Values

A summary of these assets and estimated fair values at the Closing Date is as follows (in thousands):

	Value of Intangible
	Assets Acquired
CERE-110 for the treatment of Alzheimer's disease	$	1,640
CERE-120 for the treatment of Parkinson's disease		230
Total identifiable intangible assets	$	1,870